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Human cytomegaloviruses (HCMVs) are important pathogens in immunocompromised patients and newborns. The viral chemokine, vCXCL-1,
of the Toledo (Tol) strain of HCMV has been implicated in HCMV virulence. Chimpanzee CMV (CCMV) has several genes with similarity
to the vCXCL-1Tol gene, UL146. In order to test whether the CCMV viral chemokine, vCXCL-1CCMV, is similar to vCXCL-1Tol, we
characterized its function in vitro. Receptor binding, activation, chemotaxis, signaling, and apoptosis in neutrophils were compared between
vCXCL-1Tol and vCXCL-1CCMV and host chemokines. Although the homologues had similar activation potentials, chemotactic properties, and
signaling, vCXCL-1CCMV had a ∼70-fold lower affinity for CXCR2 and displayed differences in integrin upregulation and neutrophil apoptosis.
These data demonstrate that in spite of extensive amino acid variability in vCXCL-1, CCMV may provide a model for assessing the role of
vCXCL-1 in CMV pathogenesis in vivo.
© 2007 Elsevier Inc. All rights reserved.Keywords: Chimpanzee cytomegalovirus; Chemokine; vCXCL-1; UL146; Chemotaxis; CXCR2; Neutrophils; ApoptosisIntroduction
Human cytomegalovirus (HCMV) is a ubiquitous β-herpes-
virus, infecting between 50% and 90% of the population (Pass,
1985). Although asymptomatic in most cases, HCMV can cause
serious complications in immunocompromised patients and
newborns. Reactivation of latent HCMV or primary HCMV
infection increases graft versus host disease (McCarthy et al.,
1992), organ rejection in transplant patients (Ljungman, 1996),
and inflammatory diseases such as gastroenteritis and retinitis in
AIDS patients (Cheung and Teich, 1999). Congenital HCMV
infection is the leading cause of infectious hearing loss in infants
(Pass, 2001) and can lead to long-term sequelae such as learning
disabilities and mental retardation. Due to the life-long effects
associated with CMV congenital infections, the Institute of
Medicine lists the development of a CMV vaccine as one of its
top five priorities (Arvin et al., 2004). In an effort to develop a⁎ Corresponding author. Fax: +1 865 974 4007.
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doi:10.1016/j.virol.2007.03.002safe and effective vaccine, a more thorough understanding of
HCMV pathogenesis is needed.
HCMV has a number of genes that encode proteins capable of
suppressing or modulating the immune system that have been
implicated in pathogenesis (Mocarski, 2002;Wiertz et al., 1997).
Every aspect of the immune response can be altered including
class I and class II antigen processing and presentation as well as
inflammatory responses (Mocarski, 2002). Proteins that alter
immune responses likely contribute to HCMV's pathogenesis.
Therefore understanding HCMV immune modulators may aid
in designing safe and effective vaccines or potential antiviral
therapeutics.
The Toledo strain of HCMV, a strain that is known to cause
disease in humans (Quinnan et al., 1984), was shown to produce
a functional viral chemokine, vCXCL-1 (Penfold et al., 1999).
Although chemokines are divided into four families, the
majority of chemokines fall into the two families, CC and
CXC chemokines, based on the spacing of their amino terminal
cysteines. The presence of a glutamate, leucine, arginine (ELR)
motif amino terminal to the CXC further subclassifies the CXC
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CXC family of chemokines was initially thought to function
exclusively on neutrophils (Hebert et al., 1991) but also induces
angiogenesis via endothelial cells (Addison et al., 2000;
Coughlan et al., 2000; Strieter et al., 1995). The vCXCL-1
protein is a member of the ELR-CXC chemokine family (Sparer
et al., 2004). Indeed, vCXCL-1Tol (the subscript indicates the
strain from which the protein is derived, e.g. Toledo) was shown
to bind exclusively to CXCR2 and to induce calcium flux and
chemotaxis of neutrophils (Penfold et al., 1999). Penfold et al.
speculated that the induction of neutrophils could be used as a
means for viral dissemination, thus increasing virulence. In fact
HCMV can be isolated from neutrophils in immunocompro-
mised patients (Martin et al., 1984; Saltzman et al., 1988; van der
Bij et al., 1988) and neutrophilic infiltrates are found in AIDS
patients who have CMV related retinitis (Holland et al., 1983;
Pepose et al., 1985). The UL146 gene, which produces the
vCXCL-1 protein, is absent in an attenuated lab strain, AD169,
and based on these findings, the vCXCL-1 protein has been
hypothesized to be a potential virulence factor (Cha et al., 1996).
Testing this hypothesis in vivo is limited by the species
specificity of cytomegaloviruses. In this study we wished to
further evaluate the effects of vCXCL-1Tol on neutrophil
function in vitro and to compare those findings with host
chemokines and a related chemokine from chimpanzee CMV
(CCMV).
vCXCL-1CCMV was chosen for comparison to vCXCL-1Tol
to evaluate whether the conservative substitution in vCXCL-
1CCMV's ELR motif and variability in the N-loop region, both
of which are considered important to receptor binding and
triggering for host chemokines (Clark-Lewis et al., 1993,
1994; Lowman et al., 1996), affect protein function. In our
work presented here, we compare differences in receptor
binding affinity, cellular activation, signal transduction,Fig. 1. Amino acid alignment of the mature forms of CXCL1, CXCL8, vCXCL-1CC
alignment. The N-loop region is residues 10–20. vCXCL-1CCMV is 22% identical and
identical and 40% similar to CXCL8.chemotaxis, upregulation of adhesion molecules, and anti-
apoptotic functions, between vCXCL-1Tol, vCXCL-1CCMV,
and host chemokines.
Results
Comparison of amino acid sequences
Sequence analysis indicates vCXCL-1CCMV has limited
homology to vCXCL-1Tol, CXCL1, and CXCL8 (Fig. 1).
Although the amino acid sequences show relatively low
homology, all share important characteristics of CXC chemo-
kines, including an N terminal signal peptide, spacing of the
four conserved cysteines, and ELR like motif. The ELR-CXC
motif is present in all CXC chemokines that bind CXCR1 and
CXCR2. While the vCXCL-1 from clinical isolates sequenced
previously display conservation of this ELR-CXC motif (Arav-
Boger et al., 2005; Lurain et al., 2006; Prichard et al., 2001), it is
modified in vCXCL-1CCMV with an L→M conservative
substitution. Even though this is a conservative substitution,
this replacement could affect neutrophil function based on
published results showing that host chemokines with a modi-
fied ELR motif are subsequently impaired for receptor
binding and calcium mobilization (Clark-Lewis et al., 1993;
Hebert et al., 1991). Overall, the vCXCL-1Tol and vCXCL-
1CCMV proteins are 52% similar with only 22% identity. This
observation mirrors the low identity previously observed in
the sampling of human clinical isolates, suggesting that only
core, conserved regions of the protein are required for
functionality. The N-loop region is another domain that is
important for receptor engagement and function. This region
lies between the second cysteine and the 310 helix usually
from amino acids 10–20 (Fernandez and Lolis, 2002). Only a
conserved proline residue within the N loop is conservedMV, and vCXCL-1Tol. Residues that are 100% conserved are indicated above the
52% similar to vCXCL-1Tol, 17% identical and 33% similar to CXCL1, and 18%
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primary amino acid sequence may have pleiotropic effects.
Alterations in these domains may lead to differences in
affinity that subsequently alter binding and/or function. We
set out to determine whether the variability within vCXCL-
1CCMV results in differences in function.
vCXCL-1 proteins can be produced and purified using the
baculovirus expression system
In order to address functional differences between the viral
chemokines, we generated both proteins using recombinant
baculovirus. We chose this system because baculovirus ex-
pression systems utilize the mammalian signal peptidase
cleavage site and generate eukaryotic glycosylation patterns
and folding. Following infection of HiFive cells with
recombinant baculovirus expressing the His-tagged viral
chemokines, the secreted protein was purified using Ni-NTA
agarose beads. A silver stain of the isolated proteins indicates
the high purity achieved in the isolation procedure (Fig. 2A).
The apparent size of both vCXCL-1CCMV and vCXCL-1Tol at
approximately 14 kDa is larger than the predicted 10 kDa. The
differences in molecular weight were due to glycosylations
(both have two predicted N-linked glycosylation sites) as
subsequent digestion with the glycosidase, PNGase F,
generated proteins of the predicted size (10 kDa) (data not
shown). Mass mapping of trypsin-digested vCXCL-1CCMV and
vCXCL-1Tol proteins confirmed the identities of the isolated
proteins (Supplemental data 1). N-terminal sequencing con-
firmed proper cleavage of the signal peptide (Fig. 2B). Proper
cleavage of the signal sequence is critical for chemokineFig. 2. vCXCL-1 protein production. (A) vCXCL-1CCMV and vCXCL-1Tol
production in baculovirus. 1 μg of 6His-tagged protein eluted from nickel beads
was run on a 15% SDS PAGE gel and silver-stained. (B) N-terminal sequencing
confirmed the predicted cleavage of the signal peptide of vCXCL-1CCMV and
vCXCL-1Tol.function (Clark-Lewis et al., 1991). In fact, alteration by
the addition or deletion of a single amino acid has been
shown to abrogate the function of some chemokines (Proud-
foot et al., 1996, 1999). N-terminal sequencing indicated the
signal peptide of vCXCL-1CCMV was cleaved at the threonine
residue directly preceding the EMR-CXC motif as predicted
by the SignalP program (Fig. 2B). Of the two possible
cleavage sites predicted for vCXCL-1Tol, cleavage occurred at
the threonine residue (T23) corresponding to that of vCXCL-
1CCMV. Our data show that the T23 site is the preferential
cleavage site. A synthetic vCXCL-1Tol based on the other
signal sequence cleavage site (Y18) was previously shown to
be 100-fold less active than that cleaved at the threonine
residue corresponding to the N terminus in our preparations
(Penfold et al., 1999). This is the first confirmation that this
cleavage site is used for naturally processed vCXCL-1Tol
indicating that the active form of the protein is preferentially
synthesized.
vCXCL-1CCMV induces intracellular calcium release in PBN
With the differences noted in primary amino acid sequence,
we assessed whether these differences correlate with differential
functions. The release of intracellular calcium is often used as an
indicator of chemokine induction of cellular activation (Murphy,
2003). We examined the ability of vCXCL-1CCMV to induce
intracellular calcium mobilization in freshly isolated PBN. The
dose response analyses of vCXCL-1CCMV and vCXCL-1Tol
showed similar activation potential (Fig. 3A), demonstrating that
the amino acid differences did not alter triggering of intracellular
calcium release.
Previous work demonstrated the ability of vCXCL-1Tol to
desensitize PBN activation following exposure to a number of
human chemokines, including CXCL1 (Penfold et al., 1999).
Receptor desensitization is determined by the receptor affinity
for the chemokine, phosphorylation of the carboxyl terminus,
and subsequent β arrestin binding. We confirmed the ability of
vCXCL-1Tol to desensitize PBNs to CXCL1 activation.
However, CXCL1 is not able to completely desensitize to
vCXCL-1Tol (Fig. 3B).
The desensitization profile of vCXCL-1CCMV (Fig. 3C) was
compared to that of vCXCL-1Tol. Unlike vCXCL-1Tol,
vCXCL-1CCMV is unable to completely desensitize PBN to
activation via CXCL1. In addition CXCL1 is able to com-
pletely desensitize to vCXCL-1CCMV added to PBN following
CXCL1. Because CXCL1 binds only to CXCR2, its ability to
inhibit vCXCL-1CCMV calcium mobilization suggests that
vCXCL-1CCMV, like vCXCL-1Tol, binds via CXCR2. Treat-
ment of cells with the CXCR2 inhibitor, SB 225002, prior to
exposure to vCXCL-1CCMV resulted in minimal calcium
mobilization further indicating that vCXCL-1CCMV functions
via CXCR2 (data not shown). The incomplete desensitization
to CXCL1 is likely due to a lower affinity of human CXCR2
(hCXCR2) for vCXCL-1CCMV. Alternatively, a reduced ability
of vCXCL-1CCMV to initiate phosphorylation of CXCR2 to the
same degree as vCXCL-1Tol could result in lower levels of
receptor desensitization (Richardson et al., 2003). These results
Fig. 3. vCXCL-1CCMV has a similar activation threshold as vCXCL-1Tol and can be desensitized by CXCL1. (A) Changes in fluorescence were measured over time
after exposure of human PBN to different concentrations of vCXCL-1CCMV or vCXCL-1Tol. Arrows indicate the time of addition of the chemokine.
(B) Desensitization profile of vCXCL-1Tol/CXCL1 and (C) vCXCL-1CCMV/CXCL1. 100 nM of CXCL1, vCXCL-1CCMV, or CCL5 were added at the times
indicated by the arrow. A second addition of 100 nM of the indicated chemokine was added at 90 s. Changes in fluorescence were measured over time. Data is
representative of five experiments.
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vCXCL-1CCMV such that different desensitization patterns are
triggered.
vCXCL-1CCMV has reduced affinity for CXCR2 compared to
vCXCL-1Tol or CXCL1
The ability of CXCL1 to desensitize to vCXCL-1CCMV in the
calcium mobilization assays suggests this viral chemokine
binds to CXCR2. However, the lack of complete desensitization
when vCXCL-1CCMV was used to desensitize against CXCL1,
could reflect differences in receptor binding affinity for the
viral chemokine. To test this possibility, competition-binding
assays were used to evaluate the ability of vCXCL-1CCMV to
compete for binding to CXCR2. vCXCL-1CCMV was able to
compete with 125I CXCL1 for binding to hCXCR2, albeit ata higher 50% inhibitory concentration (IC50) than that
required for CXCL1 or vCXCL-1Tol (Fig. 4). We conclude
that vCXCL-1CCMV binds to hCXCR2 but with a lower
affinity than vCXCL-1Tol (vCXCL-1Tol IC50=0.9 nM vs.
vCXCL-1CCMV IC50=65 nM) and this may explain the dif-
ferences in desensitization patterns seen in Fig. 3C. (i.e. CXCL1
can prevent subsequent calcium flux via vCXCL-1CCMV while
vCXCL-1CCMV cannot desensitize to exposure to CXCL1).
Affinity may not be the sole explanation for the differences
between vCXCL-1Tol desensitization patterns with CXCL1
(Fig. 3B), yet no of difference in the calcium flux activation
potentials (Fig. 3A). The viral chemokines could be
engaging the receptors such that β arrestins are not activated
as efficiently. This would explain the differences in
desensitization patterns while not affecting the activation
potentials.
Fig. 4. vCXCL-1CCMV binds with less affinity than vCXCL-1Tol to CXCR2. 293
cells stably expressing only CXCR2 were incubated with a constant amount of
125I-CXCL1 and increasing amounts of unlabeled chemokines. Calculated IC50
values are indicated in molar concentrations in parentheses. Data is repre-
sentative of two experiments.
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An important function of chemokines is their ability to
induce chemotaxis of a variety of cells. ELR-CXC chemokines
and vCXCL-1Tol trigger migration of neutrophils (Penfold et
al., 1999). We tested the ability of vCXCL-1CCMV to induce
migration of human PBN using a modified Boyden chamber.
vCXCL-1CCMV induces migration of neutrophils with equal
potency as the host chemokine CXCL1 (Fig. 5) and vCXCL-
1Tol (Penfold et al., 1999). Once again, in spite of differences in
affinity for hCXCR2 and primary amino acid sequences,
vCXCL-1CCMV chemoattracts PBNs efficiently.
vCXCL-1CCMV activates ERK and Akt signaling pathways
The differences in affinity between the chemokinesmay affect
functional activation (Clark-Lewis et al., 1991, 1994; Geiser et
al., 1993; Wu et al., 1996) as we observed with desensitizationFig. 5. vCXCL-1CCMV induces migration of neutrophils. Migration assays were
performed by loading human PBN onto the upper chamber of a 96-well plate
fitted with a 5 μm filter with increasing amounts of chemokine loaded in the
lower chamber. Results are reported as a chemotactic index of the number of
cells migrated divided by the random migration±S.D. Data is representative
from three experiments.patterns (Fig. 3). Upon CXCR2 binding, G protein signal
transduction cascades are activated (De Lean et al., 1980). Two of
the central signal transduction cascades activated upon CXCL1
binding to CXCR2 are the extracellular signal-related protein
kinase (ERK), a member of the mitogen-activated protein (MAP)
kinase family (Shyamala and Khoja, 1998) and protein kinase
B/Akt pathway, which is activated via the phophoinositide-3
kinase signaling cascade. The activation of the ERK and Akt
signaling pathways are triggered following exposure to chemo-
kines and β-arrestin activation (Lefkowitz and Shenoy, 2005). In
order to assess whether the differences in binding to CXCR2
induce different signaling cascades, we analyzed the activation
profile of differentiated HL-60 cells stably expressing CXCR2
following exposure to vCXCL-1CCMV. HL60s were used due to
the difficulty of isolating fresh PBNs without inadvertent signal
transduction activation and host-to-host variation. Exposure of
differentiated HL-60 cells to vCXCL-1CCMV and vCXCL-1Tol
resulted in phosphorylation of both ERKandAkt to similar levels
as the CXCL8 and CXCL1 controls (Fig. 6). At least for these
two important signaling pathways, the affinity for hCXCR2 does
not markedly impact activation.
vCXCL-1CCMV upregulates CD11b and CD11c on the surface
of PBN
β2 integrins, including CD11a, CD11b, and CD11c, are
membrane bound receptors present on leukocytes that are
necessary for PBN adhesion to and migration across the
endothelium (Mayadas and Cullere, 2005). Because of their
potential importance in recruitment of PBN to the site of
CMV infection, we tested the ability of vCXCL-1CCMV and
vCXCL-1Tol to alter surface expression of these receptors on
PBN. Exposure of human PBN to vCXCL-1CCMV and
vCXCL-1Tol resulted in no change in the levels of CD11a
expressed on the cell surface (Fig. 7). However, CD11b and
CD11c levels increased upon exposure to vCXCL-1CCMV
(30% and 12% above control respectively) and to similar levels
as CXCL1 (51% and 11%) (Fig. 7). Interestingly, vCXCL-1Tol
also increased expression of these proteins on PBN but to
somewhat higher levels (106% and 36%) compared to CXCL1
or vCXCL-1CCMV. PBN exposed to CXCL8 showed similar
levels of CD11b/c expression (106% and 46%) as thoseFig. 6. Both viral and host chemokines activate the ERK and Akt pathways.
Differentiated HL-60 cells stably expressing CXCR2 were stimulated with
100 nM chemokine for 1 min at room temperature and lysed instantly. Lysates
were immunoblotted using antibodies against the phosphorylated (p) and
unphosphorylated ERK and Akt proteins as indicated. This is representative of
two experiments.
Fig. 7. vCXCL-1Tol and vCXCL-1CCMV differentially increase CD11b and CD11c expression on the surface of neutrophils. Human PBN were incubated in the
presence of 100 nM of different chemokines (vCXCL-1Tol, vCXCL-1CCMV, CXCL1, or CXCL8) and labeled with fluorescently-conjugated antibodies against CD11a,
CD11b, and CD11c. The table summarizes the flow cytometry data and is expressed as percent change in the mean fluorescent intensity compared to non-stimulated
PBN. This is a representative experiment of three experiments.
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chemokines differentially induce adhesion molecule upregula-
tion: vCXCL-1Tol is similar to CXCL8 stimulation and
vCXCL-1CCMV is similar to CXCL1. These data show that
amino acid differences between these chemokines can lead to
different activation profiles on PBN that could affect their
functions in vivo.
vCXCL-1CCMV decreases apoptosis of human PBN
PBN normally undergo apoptosis in 24–48 h (Haslett,
1992). Because PBN play a role in the dissemination of
HCMV (Gerna et al., 1992, 2000), HCMV may have evolved
viral chemokines that alter PBN viability. We assessed the
capacity of vCXCL-1CCMV and vCXCL-1Tol to alter apoptosis
of PBN. We found that vCXCL-1CCMV and vCXCL-1Tol de-
creased apoptosis (17% vs. 29% respectively) (Fig. 8). This
decrease was similar to CXCL1 (21%). However, it was not as
great as the reduction following exposure to CXCL8 (44%).
Any differences in the longevity of neutrophils could affect
viral survival or dissemination in vivo, which eventually
affects HCMV pathogenesis.
Discussion
The significant findings of this paper are that two distantly
related viral chemokines (vCXCL-1Tol and vCXCL-1CCMV)
have similar functions in spite of distinct differences in affinityfor CXCR2 and amino acid composition in the N loop and ELR
motifs. These regions of host chemokines have been shown to
play a role in receptor binding and activation (Clark-Lewis et
al., 1993; Fernandez and Lolis, 2002; Hebert et al., 1991).
Although vCXCL-1CCMV was able to bind CXCR2, it was not
able to bind with as high of an affinity as vCXCL-1Tol or
CXCL1 in competition binding studies (Fig. 4). This difference
could reflect the difference in affinity of vCXCL-1CCMV for
human CXCR2 versus chimpanzee CXCR2 in these assays.
However, the CXCR2 receptor in these two species is highly
conserved. Chimpanzee CXCR2 is 99% identical to human
CXCR2 based on amino acid comparisons. Only 2 amino acids
out of 355 are different. These two amino acids are located in
transmembrane regions 5 and 7 (Alvarez et al., 1996).
Importantly, the transmembrane regions of CXCR2 that are
known to be important for receptor structure are conserved
between the human and chimpanzee receptors (Baggiolini et al.,
1997). It is possible that binding motifs and structural
differences not yet identified could result in differential binding
of vCXCL-1CCMV to hCXCR2, although this seems unlikely.
It is perhaps more likely that differences in the viral chemo-
kines themselves are responsible for the differences in binding
affinity. This may be due in part to the mutated ELR motif
(L→M) present in vCXCL-1CCMV. The ELR motif is known to
be important in receptor binding and signaling (Clark-Lewis et
al., 1991; Schraufstatter et al., 1993). Mutagenesis of each of the
ELR residues of CXCL8 reduced the ability of CXCL8 to
competitively bind to neutrophils and CXCR2 expressing cell
Fig. 8. vCXCL-1CCMV and vCXCL-1Tol reduce apoptosis in neutrophils. Human PBN were incubated for 24 h in the presence of either viral or human chemokines
(100 nM). After incubation, cells were labeled with annexin-FITC and propidium iodide and then analyzed by flow cytometry. The percent reduction in apoptosis
relative to the non-stimulated cells is summarized in the table. This is a representative experiment of five experiments.
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completely eliminate receptor binding and other regions, such as
the N-loop region, are also important in receptor binding
(Fernandez and Lolis, 2002). vCXCL-1CCMV only shares the
single amino acid, proline, with CXCL1 in this region and the
sequence diversity in this region may contribute to the
differences seen in binding affinity. Additionally, the presence
of a glycine at residue 31 has been shown to be important for
receptor binding (Clark-Lewis et al., 1994, 1995; Li et al., 2002).
vCXCL-1C956 from a clinical isolate of HCMVhas a substitution
at the G31 residue but shows equivalent binding to CXCR2 and
an equal capacity for inducing calcium mobilization to levels
comparable to CXCL1 (unpublished data). This data demon-
strates that the results seen with vCXCL-1CCMV, which also has a
substitution at this residue, is not solely responsible for its lower
binding affinity to CXCR2. Finally, the carboxyl terminus plays
some role in the function of chemokines. Although not thought
to be important in all cases, the carboxyl terminal region of
CXCL1 has been implicated in receptor binding (Roby and
Page, 1995). The C-terminal region of the viral chemokines is
considerably longer than that of CXCL1 and CXCL8 and may
contribute to differential binding or signaling of the receptor
(Fig. 1 and Penfold et al., 1999).
Evolution has directed the variation of HCMV genes such
that viral genes have similar functions with limited homology to
host genes. As discussed above, vCXCL-1 shows sequence
variation from its cellular counterpart, CXCL1. Additionally,
sequencing of human CMV clinical isolates has revealed
extreme sequence variability between strains, with only limitedregions of conservation and identities below 30% (Arav-Boger
et al., 2006b; Prichard et al., 2001). Similarly UL144, a viral
tumor necrosis factor (TNF)-alpha-like receptor gene, displays
high variance in its sequence between clinical strains and
correlates with severity of congenital disease (Arav-Boger et al.,
2006a; Arav-Boger and Pass, 2002). Both human and rhesus
CMVs encode interleukin 10 homologues, which retain
functionality despite a sequence identity of less than 30% to
their cellular counterparts (Kotenko et al., 2000; Spencer et al.,
2002). Such variability among secreted and surface-displayed
proteins may be driven by selective immune pressures, although
why certain genes appear more susceptible to these pressures
than others is unknown.
An important question is whether the reduced binding affinity
by vCXCL-1CCMV results in differences in the functional
capacity of this protein. Relative differences in activity between
CXCL8 and vCXCL-1CCMV can be difficult to assess based on
the ability of CXCL8 to bind and signal via both CXCR1 and
CXCR2, whereas vCXCL-1CCMV, based on our data, only
activates CXCR2. Therefore, we also compared the biological
activity of vCXCL-1CCMV to the CXCR2-specific chemokine,
CXCL1. As we have shown, vCXCL-1CCMV induces activity in
most biological assays comparable to that of CXCL1. Given the
lower binding affinity of vCXCL-1CCMV, we also tested the
activation profile of vCXCL-1CCMV at 1 μM, which is 15 fold
above the IC50, to ensure complete saturation of all expressed
receptors. However, the higher concentration of vCXCL-1CCMV
did not result in a greater calcium flux than at 100 nM, therefore
it is reasonable to assume that the receptors were saturated at the
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conclude that lower receptor binding affinity does not correlate
with a reduction in biological activity when compared with
CXCL1. One exception where reduced binding affinity may be
important is the ability of vCXCL-1CCMV to completely
desensitize neutrophils upon subsequent exposure to CXCL1.
In this case, the ability of CXCL1 to compete more effectively
(i.e. higher binding affinity) for binding to CXCR2 allows it to
displace vCXCL-1CCMV and induce a second wave of calcium
mobilization. Interestingly, vCXCL-1CCMV was unable to
desensitize PBN to CXCL1 even when used at a 10-fold higher
concentration compared to CXCL1 (data not shown) suggesting
the lack of complete desensitization may be due in part to
differential activation and phosphorylation of CXCR2. Phos-
phorylation of G protein-coupled receptors prevents reassocia-
tion of the G protein and the receptor, resulting in a receptor that
is desensitized to further stimulation by ligand (Neel et al.,
2005).
vCXCL-1Tol was previously found to functions via CXCR2,
inducing calcium mobilization and chemotaxis of PBN with a
potency comparable to CXCL8 (Penfold et al., 1999). We have
verified similar findings for the CCMV viral chemokine,
vCXCL-1CCMV. vCXCL-1CCMV showed a similar profile of
calcium mobilization as vCXCL-1Tol at the concentrations
tested. Additionally, vCXCL-1CCMV was able to induce
migration of neutrophils as effectively as CXCL1. The ability
of vCXCL-1CCMV to induce PBN chemotaxis could enable the
virus to modulate the immune response to benefit viral survival
or dissemination. An example of a viral chemokine that
functions in viral dissemination is the MCK2 chemokine from
murine cytomegalovirus (MCMV) (Fleming et al., 1999;
Saederup et al., 1999, 2001). Infection of mice with MCMV
lacking the MCK chemokine gene resulted in decreased
inflammation at the site of infection and dissemination of the
virus. This evidence illustrates the ability of viral chemokines to
alter the immune response in vivo (Saederup et al., 2001).
Although these chemokines are from two different chemokine
families (CXC for vCXCL-1CCMV and CC for MCK2), they
could be functional homologues. This is a common theme for
CMVs. Other immune modulatory proteins such as the class I
down regulating proteins from the M152 gene in MCMV
(Ziegler et al., 1997) and the US2, US3, and US11 genes in
HCMV (Gewurz et al., 2001; Landolfo et al., 2003; Rehm et al.,
2002), lack sequence homology yet both viruses achieve the
same end result of down-regulation of antigen presentation.
Chemotaxis of circulating neutrophils is dependent on
adhesion to and extravasation across the endothelium. This
process can be mediated by the interaction of β2 integrins
present on the surface of PBN with their ligands on endothelial
cells. The β2 integrin family includes CD11a, CD11b, CD11c,
and CD11d. Previous studies demonstrated the ability of the
chemokines, CXCL8 and CXCL1, to upregulate CD11b
expression (Detmers et al., 1990). Here we demonstrate that
both vCXCL-1CCMV and vCXCL-1Tol increase CD11b and
CD11c expression on the cell surface. Furthermore, CXCL8
upregulation of CD11b on PBN involves the ERK signaling
pathway (Takami et al., 2002), which was shown to beupregulated by both viral chemokines (Fig. 6). Therefore,
these viral chemokines could enhance the ability of PBN to
adhere to and cross the endothelium allowing migration of
neutrophils through the tissue to the site of infection.
Regulation of apoptosis of neutrophils could also provide
an advantage to HCMV by allowing PBN to survive and
disseminate HCMV. In fact HCMV produces several proteins
that alter apoptosis in infected cells (McCormick et al.,
2005; Smith and Mocarski, 2005). Our results show that
vCXCL-1CCMV, vCXCL-1Tol, and CXCL1 reduce apoptosis to
similar levels. CXCL8 shows the highest reduction in apoptosis.
However this chemokine has also been shown to alter apoptosis
primarily via CXCR1 (Glynn et al., 2002) through activation of
the ERK and Akt pathways in neutrophils (Akgul et al., 2001;
Khreiss et al., 2004). The similarity in vCXCL-1CCMV and
vCXCL-1Tol activation of the ERK and Akt pathways suggests
that other pathways must also be involved. Prolonging PBN
survival would be advantageous for HCMV. The longer the
neutrophil is viable, the greater the chance it will be used for
dissemination (Grundy et al., 1998).
In conclusion, we have shown that the CCMV viral
chemokine has similar biological activities to vCXCL-1Tol and
CXCL1 except for integrin upregulation and inhibition of
apoptosis. This is in spite of differences in binding affinities
and amino acid variability in the N-loop region and ELR
motif. A similar example is found in human herpesvirus 8
(HHV8) viral chemokines vMIP I and vMIP II (Boshoff et al.,
1997; Kledal et al., 1997). This chemokine has limited homo-
logy (38% and 41% respectively) to host chemokines CCL2
(MIP1α) and CCL5 (RANTES) (Fernandez et al., 2000). These
chemokines have similar functions to host chemokines yet can
act as antagonists and bind to additional host chemokine re-
ceptors. Although we have not found antagonistic functions for
vCXCL-1s, vMIP II is yet another example of a herpesvirus
evolving a chemokine with unique functions.
We can infer from our data that very simple structural
motifs guide receptor binding and activation rather than
specific amino acid-to-amino acid interactions. The eotaxin
family of host chemokines provides a similar example. These
chemokines also have considerable variability yet slight
differences in binding and activation (Forssmann et al.,
1997; Kitaura et al., 1999; Shinkai et al., 1999; White et al.,
1997). All eotaxins bind and/or activate the same eotaxin
receptor, CCR3, in spite of very little amino acid identity
(Duchesnes et al., 2006). There is some variability in the
responses to the different eotaxins leading to speculation that
these proteins may exist to “fine-tune” their interaction with
their receptor to produce different biological outcomes. We
propose that the variability in the viral chemokines helps to
fine tune the neutrophil response, which allows for more
efficient HCMV dissemination. This explains the high degree
of variability that occurs naturally in HCMV isolates (He et al.,
2006) and between their homologous host chemokines. The
vCXCL-1s from different strains of HCMVs could allow for
increased dissemination via fine-tuned alterations of apoptosis
and integrin expression that provides a survival advantage in
the specific hosts.
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Cells and viral DNA
SF9 insect cells were cultured in SF900 II media
(Gibco) supplemented with 5% FBS, 2 mM L-glutamine,
and 1% gentamicin (Biowhittaker). HiFive insect cells
(Cellgro) were cultured in Insect Express media (Biowhit-
taker). Chimpanzee cytomegalovirus DNA was generously
provided by Dr. Gary Hayward (Johns Hopkins School of
Medicine).
Sequence analysis
Amino acid sequence alignments of vCXCL-1Tol and
vCXCL-1CCMV were performed using the clustalW algorithm
of MegAlign sequence analysis software (DNASTAR). SignalP
3.0 (http://www.cbs.dtu.dk/services/SignalP/) was used to pre-
dict the signal sequence cleavage sites of vCXCL-1CCMV and
vCXCL-1Tol.
Protein purification and analysis
The vCXCL-1 gene, UL146, was PCR amplified from
either HCMV or CCMV viral DNA and cloned into the
baculovirus transfer plasmid 1392 (Invitrogen), which con-
tains homologous regions for recombination into the ba-
culovirus genome. PCR primers were designed to include the
coding sequence for six histidines on the carboxyl terminus
of the proteins for purification and Western blotting. SF9
cells were transfected with the plasmid construct and
Sapphire linearized baculovirus DNA (Orbigen). Recombi-
nant baculovirus containing the UL146 gene from either
HCMV or CCMV was titered and used to infect HiFive cells
for optimum protein expression. Cells were harvested after
48 h of incubation and protein was isolated from the super-
natants using Ni-NTA agarose beads (Qiagen) and resus-
pended in PBS. Protein concentration was quantified using
the Bradford assay (Biorad) according to the manufacturer's
instructions.
N-terminal sequencing was used to verify cleavage of the
signal peptide. 100 pmol of vCXCL-1CCMV and vCXCL-1Tol
was run on a 15% SDS-PAGE gel and then blotted onto
PVDF membrane. The protein bands were excised from the
membrane and analyzed by the Stanford PAN facility using de
novo N-terminal sequencing.
Receptor binding analysis
The ability of vCXCL-1CCMV and vCXCL-1Tol to compete
for binding to CXCR2 was evaluated as previously described
(Penfold et al., 1999). Briefly, HEK293 cell transfectants
over-expressing CXCR2 were incubated with 125I-labeled
CXCL1 and increasing concentrations of unlabeled chemo-
kines. Cells were collected on glass filters, washed, and
bound radioactivity was measured by liquid scintillation
counting.Activation of signal transduction pathways
Differentiated HL-60 cells stably expressing CXCR2 were
stimulated with different chemokines at 100 nM for 1 min at
room temperature and lysed in 2× RIPA buffer containing
protease and phosphatase inhibitors (Walker et al., 2005). 20
ug of total protein was then run on a 10% SDS PAGE and
immunoblotted with antibodies against phosphorylated Akt
(Thr 308) (Cell Signal Technology), Akt, phosphorylated
ERK, and ERK (Santa Cruz Biotechnology).
Neutrophil isolation
Peripheral blood neutrophils (PBN) were isolated from
EDTA-treated blood from healthy human volunteers using
dextran sedimentation and density gradient centrifugation as
previously described (Markert et al., 1984). Erythrocytes
were removed by hypotonic lysis. Neutrophils were resus-
pended in buffer or media as stated for the individual
assays. Viable neutrophils were quantified by trypan blue
exclusion. The use of human subjects has been approved by
the University of Tennessee Institutional Review Board
(IRB# 6476B).
Intracellular calcium mobilization assays
Release of calcium from intracellular stores was deter-
mined in freshly isolated PBN resuspended in PBS. Cells
were loaded with 3 μg/ml Indo-1-AM (Molecular Probes)
for 60 min at 37 °C. Cells were washed one time with PBS
and diluted to 3–5×106 cells/ml in Hanks' balanced salt
solution (HBSS) containing Ca2+ and Mg2+ and 1% FBS.
Chemokines were added at varying concentrations to 2 ml
of cells. All host chemokines were purchased from Pep-
rotech (Rocky Hill, NJ) and endotoxin levels were less than
0.1 ng per μg (1 EU/μg). Calcium release was measured
using a Photon Technology International Spectrophotometer
(New Jersey) at an excitation of 350 nm. Relative intra-
cellular calcium levels were expressed as the ratio of
emissions at 490 nm to the emissions at 400 nm (Sparer et
al., 2004).
PBN migration assays
Migration assays were performed on human PBN
resuspended in HBSS with 0.1% BSA and 10 mM HEPES.
Assays were performed in triplicate in 96-well chemotaxis
plates. 20 μl of chemokines were loaded at varying con-
centrations into the lower well of the modified Boyden
chamber (Neuroprobe) and fitted with a 5 μM filter. 1×106
PBN in 30 μl were added to the upper well. The cells were
incubated for 3 h at 37 °C. Migration of PBN was measured
by direct count of cells that had migrated through the filter
into the lower chamber. The chemotactic index was calculated
as the number of cells that migrated in the presence of
chemokine divided by the number of cells that migrated due
to buffer only.
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PBN were resuspended in RPMI-1640 (Biowhittaker) with
1% FBS and added to a 96-well plate at 1×106 cells/well.
Chemokines were added to the wells at a final concentration of
100 nM. Plates were incubated at 37 °C, 5% CO2 for 24 h. Cells
were labeled with AnnexinV and propidium iodide (PI) using
the Annexin V Kit (Caltag) according to the manufacturer's
instructions. Cells were analyzed by flow cytometry using
FACS Calibur (Beckman-Coulter) within 1 h.
CD11 staining
PBN were resuspended in RPMI-1640 (Biowhittaker) with
1% FBS and added to a 96-well plate at 1×106 cells/well.
PBN were exposed to 100 nM of chemokines for 2 h at 37 °C
and 5% CO2. Cells were washed with PBS and blocked with
1% goat serum. PBN were incubated with fluorescently con-
jugated CD11a, CD11b, and CD11c antibodies (Caltag) on ice
and fixed with 4% paraformaldehyde. Cells were analyzed by
flow cytometry.
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